T-436 P.001

11/4/2004

Date

F-716

Customer No. 28880		CENTRAL FAX CENTER	Confirmation No. 2435
PTO/SE/21 (03-03)  NOV 0 4 2004 Approved for use through 04/30/2003. OMB 0651-0031  U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  Under the Paperwork Reduction Act of 1995, no genous am required to respond to a collection of information unless hidisplays a valid OMB control number.			
Oliver the Palos with Abdustion Active to September 1		Application Number	08/812,508
TRANSMITTAL FORM (to be used for all correspondence after inklal filling)		Filing Date	March 7, 1997
		First Named Inventor	Janak Khimchand Padia, et al.
		Art Unit	1624
		Examiner Name	Deepak R. Rao
Total Number of Pages in This Submission	24	Attorney Docket Number	5117-C1-01-MG
ENCLOSURES (Check all that apply)			
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Remar AUTHO	RIZATION TO CHARGE T	After Allowance Communication to a Technology Center (TC)  Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below):  THE FEE AND ANY ADDITIONAL FEES AS VERPAYMENT TO DEPOSIT ACCOUNT
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
or Melidi Ganjeizaden	Mehdi Ganjeizadeh		
Individual Signature			
Date 11/4/2004			
117-12404			
CERTIFICATE OF TRANSMISSION/MAILING			
I hereby cartify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:Commissioner for Patents, P.O.Box 1450. Alexandria, VA 22313-1450 on the dose November 4, 2004  Typed or printed Inja Cho			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is accorded by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducine this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPTO Fax No.

Signature

703-872-9306

ov-04-2004 04:58pm From- PATENT PFIZER ANN ARBOR MI 7346222928 T-436 P.002 . F-716

Confirmation No. 2435

## RECEIVED CENTRAL FAX CENTER

5117-C1-01-MG

NOV **0 4** 2004

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: Janak Khimchand Padia, et al. EXAMINER: Deepak R. Rao

SERIAL NO. : 08/812,508 ART UNIT : 1624

FILED: March 17, 1997 PAPER NO.:

FOR : Novel Heterocycles as Cholecystokinin (CCK) Ligands

## **AMENDMENT AND RESPONSE**

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## Dear Sir:

This paper is in response to the Office Action mailed August 4, 2004. No new matter is introduced by way of this submission. Reconsideration of the captioned application in light of these amendments and the following remarks is respectfully requested.

Kindly amend this application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 22 of this paper.